Patients on incretin mimetics were at double the risk of being hospitalized for the treatment of pancreatitis compared with those taking other diabetes drugs, according to a review in the British Medical Journal. "The FDA and [European Medicines Agency] have both confirmed to the BMJ that their own analyses also show increased reporting or signals of pancreatic cancer with incretin mimetics. But they emphasise that this does not mean the relation is causal," researchers wrote.

Related Summaries